VivoSeq
Other

Avutometinib

3

Pipeline Programs↗

4

Active Trials↗

1

Companies Involved↗

Avutometinib is an early-stage landscape with 3 programs across 1 company. The most active players are Novartis.

Intelligence

Pipeline Metrics

Competitive Density

27/100

Pipeline Velocity

6/100

Mech. Concentration

50/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Novartis logo

Novartis

1 program

Phase 1

Pipeline

Programs by Phase

Preclinical
No programs
Phase 13

Avutometinib

Memorial Sloan Kettering Cancer Center

Defactinib

Verastem, Inc.

Everolimus

Novartis

Phase 2
No programs
Phase 3
No programs
Approved
No programs

Analysis

Trial Status

4

clinical trials

Recruiting3 · 75%
Active, not recruiting1 · 25%

Clinical Trials

Trial Activity

A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib
Recruiting·UUniversity of Oklahoma·Phase 2·NCT05512208·55 enrolled
Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients
Active, not recruiting·VVerastem, Inc.·Phase 1/2·NCT05074810·153 enrolled
5G-RUBY: Avutometinib and Defactinib in Malignant Brain Tumours
Recruiting·IInstitute of Cancer Research, United Kingdom·Phase 1/2·NCT06630260·182 enrolled
Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial Cancer
Recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT07318324·31 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)